McBrien Kerry, Rabi Doreen M, Campbell Norm, Barnieh Lianne, Clement Fiona, Hemmelgarn Brenda R, Tonelli Marcello, Leiter Lawrence A, Klarenbach Scott W, Manns Braden J
Arch Intern Med. 2012 Sep 24;172(17):1296-303. doi: 10.1001/archinternmed.2012.3147.
BACKGROUND Treatment of hypertension in patients with diabetes mellitus (DM) has been shown to improve cardiovascular outcomes; however, the value of intensive blood pressure (BP) targets remains uncertain. We sought to determine the effectiveness and safety of treating BP to intensive targets (upper limit of 130 mm Hg systolic and 80 mm Hg diastolic) compared with standard targets (upper limit of 140-160 mm Hg systolic and 85-100 mm Hg diastolic) in patients with type 2 DM. METHODS Using electronic databases, bibliographies, and clinical trial registries, we conducted a systematic review and meta-analysis to identify randomized trials enrolling adults diagnosed as having type 2 DM and comparing prespecified BP targets. Data on study characteristics, risk for bias, and outcomes were collected. Random-effects models were used to pool relative risks and risk differences for mortality, myocardial infarction, and stroke. RESULTS The use of intensive BP targets was not associated with a significant decrease in the risk for mortality (relative risk difference, 0.76; 95% CI, 0.55-1.05) or myocardial infarction (relative risk difference, 0.93; 95% CI, 0.80-1.08) but was associated with a decrease in the risk for stroke (relative risk, 0.65; 95% CI, 0.48-0.86). The pooled analysis of risk differences associated with the use of intensive BP targets demonstrated a small absolute decrease in the risk for stroke (absolute risk difference, -0.01; 95% CI, -0.02 to -0.00) but no statistically significant difference in the risk for mortality or myocardial infarction. CONCLUSION Although the use of intensive compared with standard BP targets in patients with type 2 DM is associated with a small reduction in the risk for stroke, evidence does not show that intensive targets reduce the risk for mortality or myocardial infarction.
已证实治疗糖尿病(DM)患者的高血压可改善心血管结局;然而,强化血压(BP)目标值的价值仍不确定。我们试图确定与标准目标值(收缩压上限为140 - 160 mmHg,舒张压上限为85 - 100 mmHg)相比,将血压治疗至强化目标值(收缩压上限为130 mmHg,舒张压上限为80 mmHg)对2型糖尿病患者的有效性和安全性。
利用电子数据库、参考文献和临床试验注册库,我们进行了一项系统评价和荟萃分析,以识别纳入被诊断为2型糖尿病的成年人并比较预设血压目标值的随机试验。收集了有关研究特征、偏倚风险和结局的数据。采用随机效应模型汇总死亡率、心肌梗死和中风的相对风险及风险差异。
使用强化血压目标值与死亡率风险显著降低(相对风险差异,0.76;95%可信区间,0.55 - 1.05)或心肌梗死风险显著降低(相对风险差异,0.93;95%可信区间,0.80 - 1.08)无关,但与中风风险降低相关(相对风险,0.65;95%可信区间,0.48 - 0.86)。对与使用强化血压目标值相关的风险差异进行的汇总分析表明,中风风险有小幅绝对降低(绝对风险差异,-0.01;95%可信区间,-0.02至-0.00),但死亡率或心肌梗死风险无统计学显著差异。
尽管与标准血压目标值相比,在2型糖尿病患者中使用强化血压目标值与中风风险小幅降低相关,但证据并未表明强化目标值可降低死亡率或心肌梗死风险。